Literature DB >> 1860261

Conventional treatment of idiopathic nephrotic syndrome and membranous nephropathy in adults.

C Ponticelli1, P Passerini.   

Abstract

This article is a review of the results of corticosteroid and immunosuppressive treatment in adults with idiopathic nephrotic syndrome. Adults with minimal-change nephropathy usually require a prolonged administration of corticosteroids to achieve remission which, in itself, carries the risk of severe and even life-threatening complications. Therefore, intravenous high-dose steroid pulses, alternate-day prednisone, short courses with cytotoxic agents and long-term administration of azathioprine have been suggested as alternatives to the classical prolonged corticotherapy. While most patients with focal-segmental glomerulosclerosis do not respond to short-term prednisone, almost half of the patients with nephrotic syndrome will attain remission with a more prolonged administration of corticosteroids and/or cytotoxic agents. A six-month course of methylprednisolone and chlorambucil preserves renal function and reduces the proteinuria in many patients with membranous nephropathy, even in the presence of initial renal insufficiency. Thus, there is growing evidence that corticosteroids and/or immunosuppressive agents can favorably alter the natural course of disease in many patients with idiopathic glomerulonephritis. However, these agents have a low therapeutic index. Further studies are needed to find more effective and less toxic treatment approaches in patients with primary glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860261

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

1.  In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis.

Authors:  A Dhondt; R Vanholder; M A Waterloos; G Glorieux; R De Smet; S Ringoir
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

2.  Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome.

Authors:  J McCauley; R Shapiro; D Ellis; H Igdal; A Tzakis; T E Starzl
Journal:  Nephrol Dial Transplant       Date:  1993       Impact factor: 5.992

3.  Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis.

Authors:  R Brunkhorst; E Wrenger; K M Koch
Journal:  Clin Investig       Date:  1994-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.